Markus Dold
Austria
Case Report
Ultra-High-Dose Long-Acting Injectable Aripiprazole in Chronic Refractory Schizophrenia: A Case Report
Author(s): Lucie Bartova, Markus Dold, Nicole Praschak-Rieder, Angela Naderi-Heiden and Siegfried KasperLucie Bartova, Markus Dold, Nicole Praschak-Rieder, Angela Naderi-Heiden and Siegfried Kasper
An intramuscular long-acting injectable (LAI) aripiprazole administered once a month as a single injection into the gluteal muscle is increasingly appreciated in the course of a long-term maintenance treatment of schizophrenia. Due to efficacy in delaying and decreasing relapse, low rates of feared side effects including extrapyramidal, metabolic and cardiovascular disturbances, aripiprazole LAI has the potential to significantly improve adherence. According to the prescribing information, the maximal starting as well as maintenance dose of aripiprazole LAI is restricted to 400 mg following a 26-day interval between the single doses.
We present a case of a 72-year-old female inpatient with an acute exacerbation of chronic refractory schizophrenia treated with aripiprazole LAI (ABILIFY MAINTENA) beyond the officially approved dose range (up to 1200 mg per month). Applying thi.. View More»
